A Director at Five Prime Therapeutics (NASDAQ: FPRX) is Selling Shares

By Carrie Williams

Yesterday, a Director at Five Prime Therapeutics (FPRXResearch Report), Franklin Berger, sold shares of FPRX for $317.4K.

This is Berger’s first Sell trade following 9 Buy transactions. This is Berger’s first transaction since reporting a Buy transaction on PTI back in October 2018

See today’s analyst top recommended stocks >>

The company has a one-year high of $13.84 and a one-year low of $3.18. Currently, Five Prime Therapeutics has an average volume of 379.00K.

In the last 30 days, insiders have sold $317.4K worth of FPRX shares and purchased $7.68M worth of FPRX shares. The insider sentiment on Five Prime Therapeutics has been positive according to 28 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.

Franklin Berger’s trades have generated a 15.3% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150.